Fluticasone Propionate Ointment label

Fluticasone Propionate Ointment

Fluticasone Propionate Ointment Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Fluticasone propionate ointment, 0.005% is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adult patients.

History

There is currently no drug history available for this drug.

Other Information

Fluticasone propionate ointment, 0.005% contains fluticasone propionate [(6α,11β,16α,17α)-6,9,-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester], a synthetic fluorinated corticosteroid, for topical dermatologic use. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.

Chemically, fluticasone propionate is C25H31F3O5S. It has the following structural formula:

image of chemical structure

Fluticasone propionate has a molecular weight of 500.6. It is a white to off-white powder and is insoluble in water.

Each gram of fluticasone propionate ointment, 0.005% contains fluticasone propionate 0.05 mg in a base of liquid paraffin, microcrystalline wax, propylene glycol, and sorbitan sesquioleate.

Fluticasone Propionate Ointment Manufacturers

  • Physicians Total Care, Inc.
    Fluticasone Propionate Ointment | Physicians Total Care, Inc.
    No Recall

    Fluticasone Propionate Ointment | Physicians Total Care, Inc.

    Fluticasone Propionate Ointment | Physicians Total Care, Inc.

    Apply a thin film of fluticasone propionate ointment, 0.005% to the affected skin areas twice daily. Rub in gently.

    Fluticasone propionate ointment, 0.005% should not be used with occlusive dressings.

    Geriatric Use

    In studies where geriatric patients (65 years of age or older, see PRECAUTIONS) have been treated with fluticasone propionate ointment, 0.005%, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.

  • E. Fougera & Co. A Division Of Fougera Pharmaceuticals Inc.
    Fluticasone Propionate Ointment | E. Fougera & Co. A Division Of Fougera Pharmaceuticals Inc.
    No Recall

    Fluticasone Propionate Ointment | E. Fougera & Co. A Division Of Fougera Pharmaceuticals Inc.

    Fluticasone Propionate Ointment | E. Fougera & Co. A Division Of Fougera Pharmaceuticals Inc.

    Apply a thin film of fluticasone propionate ointment to the affected skin areas twice daily. Rub in gently.

    Geriatric Use: In studies where geriatric patients (65 years of age or older, see PRECAUTIONS) have been treated with fluticasone propionate ointment, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.

  • Taro Pharmaceuticals U.s.a., Inc.
    Fluticasone Propionate Ointment | Taro Pharmaceuticals U.s.a., Inc.
    No Recall

    Fluticasone Propionate Ointment | Taro Pharmaceuticals U.s.a., Inc.

    Fluticasone Propionate Ointment | Taro Pharmaceuticals U.s.a., Inc.

    Apply a thin film of fluticasone propionate ointment to the affected skin areas twice daily. Rub in gently.

    Fluticasone propionate ointment should not be used with occlusive dressings.

    Geriatric Use

    In studies where geriatric patients (65 years of age or older, see PRECAUTIONS section) have been treated with fluticasone propionate ointment, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.

  • Perrigo New York Inc
    Fluticasone Propionate Ointment | Aurobindo Pharma Limited
    No Recall

    Fluticasone Propionate Ointment | Aurobindo Pharma Limited

    Fluticasone Propionate Ointment | Aurobindo Pharma Limited
    2.1 Dosage for Postherpetic Neuralgia

    In adults with postherpetic neuralgia, gabapentin tablets may be initiated on Day 1 as a single 300 mg dose, on Day 2 as 600 mg/day (300 mg two times a day), and on Day 3 as 900 mg/day (300 mg three times a day). The dose can subsequently be titrated up as needed for pain relief to a dose of 1800 mg/day (600 mg three times a day). In clinical studies, efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day with comparable effects across the dose range; however, in these clinical studies, the additional benefit of using doses greater than 1800 mg/day was not demonstrated.

    2.2 Dosage for Epilepsy with Partial Onset Seizures

    Patients 12 years of age and above


    The starting dose is 300 mg three times a day. The recommended maintenance dose of gabapentin tablets is 300 mg to 600 mg three times a day. Dosages up to 2400 mg/day have been well tolerated in long-term clinical studies. Doses of 3600 mg/day have also been administered to a small number of patients for a relatively short duration, and have been well tolerated. Administer gabapentin tablets three times a day using 600 mg or 800 mg tablets. The maximum time between doses should not exceed 12 hours.


    Pediatric Patients Age 3 to 11 years


    The starting dose range is 10 mg/kg/day to 15 mg/kg/day, given in three divided doses, and the recommended maintenance dose reached by upward titration over a period of approximately 3 days. The recommended maintenance dose of gabapentin tablets in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses. The recommended maintenance dose of gabapentin tablets in patients 5 to 11 years of age is 25 mg/kg/day to 35 mg/kg/day, given in three divided doses. Dosages up to 50 mg/kg/day have been well tolerated in a long-term clinical study. The maximum time interval between doses should not exceed 12 hours.

    2.3 Dosage Adjustment in Patients with Renal Impairment

    Dosage adjustment in patients 12 years of age and older with renal impairment or undergoing hemodialysis is recommended, as follows (see dosing recommendations above for effective doses in each indication):                                        

    TABLE 1. Gabapentin Tablets Dosage Based on Renal Function TID = Three times a day; BID = Two times a day; QD = Single daily dose
    a For patients with creatinine clearance <15 mL/min, reduce daily dose in proportion to creatinine clearance (e.g., patients with a creatinine clearance of 7.5 mL/min should receive one-half the daily dose that patients with a creatinine clearance of 15 mL/min receive).
    b Patients on hemodialysis should receive maintenance doses based on estimates of creatinine clearance as indicated in the upper portion of the table and a supplemental post-hemodialysis dose administered after each 4 hours of hemodialysis as indicated in the lower portion of the table. Renal Function Creatinine Clearance (mL/min)
    Total Daily
    Dose Range
    (mg/day)
    Dose Regimen
    (mg)
    ≥ 60
    900 to 3600
    300 TID
    400 TID
    600 TID
    800 TID
    1200 TID
    >30 to 59
    400 to 1400
    200 BID
    300 BID
    400 BID
    500 BID
    700 BID
    >15 to 29
    200 to 700
    200 QD
    300 QD
    400 QD
    500 QD
    700 QD
    15a
    100 to 300
    100 QD
    125 QD
    150 QD
    200 QD
    300 QD
     
    Post-Hemodialysis Supplemental Dose (mg)b
    Hemodialysis
     
    125b
    150b
    200b
    250b
    350b

    Creatinine clearance (CLCr) is difficult to measure in outpatients. In patients with stable renal function, creatinine clearance can be reasonably well estimated using the equation of Cockcroft and Gault:



    The use of gabapentin tablets in patients less than 12 years of age with compromised renal function has not been studied.

    2.4 Dosage in Elderly

    Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and dose should be adjusted based on creatinine clearance values in these patients.

    2.5 Administration Information

    Administer gabapentin tablets orally with or without food.

    Inform patients that, should they divide the scored 600 mg or 800 mg gabapentin tablet in order to administer a half-tablet, they should take the unused half-tablet as the next dose. Half-tablets not used within 28 days of dividing the scored tablet should be discarded.

    If the gabapentin tablets dose is reduced, discontinued, or substituted with an alternative medication, this should be done gradually over a minimum of 1 week (a longer period may be needed at the discretion of the prescriber).